As per MRFR analysis, the US Human Vaccines Market Size was estimated at 9.72 (USD Billion) in 2023. The US Human Vaccines Market Industry is expected to grow from 10.5(USD Billion) in 2024 to 17 (USD Billion) by 2035. The US Human Vaccines Market CAGR (growth rate) is expected to be around 4.478% during the forecast period (2025 - 2035).
The US Human Vaccines Market is experiencing significant growth driven by several key factors. One of the primary drivers is the increasing prevalence of infectious diseases and the recognition of vaccines as a vital public health tool. The recent COVID-19 pandemic underscored the importance of rapid vaccine development and distribution, prompting enhanced government funding and support for vaccine research and manufacturing capabilities. Additionally, the growing awareness of vaccine benefits among the population has led to increased immunization rates, contributing to overall market expansion.
Opportunities in the US market are rapidly evolving, particularly with the advent of mRNA technology and advancements in personalized medicine. Companies are exploring these innovations to create vaccines for not just infectious diseases but also for conditions like cancer. The increased focus on preventative healthcare further opens doors for vaccine development, highlighting the potential for a wider range of immunizations to enhance population health outcomes.
Recent trends in the US Human Vaccines Market include a shift towards broader vaccine acceptance, driven by educational campaigns and endorsements from health authorities. The government supports immunization programs, with initiatives like the Vaccines for Children program offering vaccines at no cost to eligible children, which helps diminish barriers to access. Moreover, the integration of digital health technologies into the vaccination process is becoming more prevalent, enabling easier tracking and management of vaccination records. The push for routine vaccinations in adults has gained traction, amplifying the demand for more comprehensive vaccine schedules. Overall, the combination of increased awareness, technological advancements, and government support continues to shape the US Human Vaccines Market significantly.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Human Vaccines Market Industry has been significantly bolstered by increased government funding and support for vaccination initiatives. The Centers for Disease Control and Prevention (CDC) reported that the federal budget for vaccination programs has reached over 4 billion USD annually, especially following the COVID-19 pandemic response, which has prioritized vaccine distribution and development. This surge in funding facilitates Research and Development efforts aimed at creating new vaccines and improving existing ones, thus driving market growth.
The National Institutes of Health (NIH) also actively invests in various vaccine-related projects, which has advanced immunization protocols and promoted public trust in vaccines. With rising healthcare demands in the US, this financial backing is expected to continue, promising a brighter future for the industry as innovative vaccine solutions become more accessible.
There is an increasing public awareness regarding the impact of preventable diseases, which is significantly impacting the US Human Vaccines Market Industry. The CDC has highlighted that vaccination rates against diseases such as measles and influenza have become critical in maintaining public health safety and reducing outbreaks. Recent statistics show that there was a 15% increase in flu vaccine coverage in the US healthcare population last season, as more individuals recognize the importance of immunizations.
This growing awareness is also fueled by advocacy groups like the Immunization Action Coalition, which work to educate the public about the benefits of vaccination, thereby promoting acceptance. This trend contributes to a sustained demand for vaccines and supports the market's expansion.
The rising incidence of infectious diseases in the United States is a critical driver for the growth of the US Human Vaccines Market Industry. According to reports from the CDC, infectious diseases such as pertussis and COVID-19 have seen resurgence, indicating a need for enhanced immunization efforts. For instance, the CDC reported that the number of pertussis cases increased by 20% from the previous year, underlining the necessity for effective vaccines to combat these diseases.
These alarming trends have prompted both government and private sector initiatives geared towards developing new vaccines. With organizations like the World Health Organization (WHO) emphasizing vaccination as a primary preventive measure, the increasing prevalence of infectious diseases will likely lead to greater investments in vaccine R&D, thus driving market growth.
The Vaccine Type segment of the US Human Vaccines Market plays a crucial role in infection control and public health by offering various methodologies to combat diseases. This segment includes diverse categories of vaccines such as Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid vaccines, each with unique characteristics, applications, and market demand. Inactivated vaccines, which are derived from killed pathogens, are widely utilized for their stability and safety profile, making them essential in ensuring broad immunization coverage in the population.
On the other hand, Live Attenuated vaccines possess the advantage of eliciting a robust immune response due to their resemblance to actual infections, providing long-lasting immunity which is indispensable for managing endemic diseases. Additionally, Subunit vaccines have gained prominence for their ability to utilize specific elements of pathogens, minimizing side effects while maintaining efficacy, thus appealing to both healthcare providers and patients. Recombinant vaccines represent a significant advancement in technology, enabling the production of vaccines that are both effective and tailored, further driving innovations in vaccine development.
Toxoid vaccines, which neutralize toxins produced by bacteria, are vital in preventing diseases such as tetanus and diphtheria, underscoring their importance in the broader vaccination landscape. The US Human Vaccines Market emphasizes the significance of these various types, considering factors such as market growth, public health initiatives, and demographic needs. As healthcare policies evolve in response to global health challenges, the strategic distribution and administration of these vaccines will remain essential to maintaining population immunity and eradicating serious infectious diseases.
Moreover, the burgeoning emphasis on Research and Development and government support play an influential role in shaping the dynamics and advancements within this segment, ultimately reflecting the broader trends in healthcare in the United States. With increasing awareness and acceptance of vaccinations driven by educational campaigns and scientific evidence, the market for these vaccine types is expected to reflect positive growth trajectories, showcasing their integral role in the continuum of healthcare and disease prevention in the US.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Human Vaccines Market, particularly within the Application segment, plays a crucial role in public health and disease prevention. Preventive Vaccines, designed to avert diseases before they occur, represent a significant portion of the market as they effectively reduce the incidence of various infectious diseases, thus supporting community immunity. Therapeutic Vaccines are emerging as vital for treating existing diseases and are gaining traction in fields like oncology, reflecting a shift towards personalized medicine.
Travel Vaccines, aiming to protect individuals from diseases prevalent in specific regions, showcase the growing importance of global travel and the need for proactive health measures in a connected world. Influenza Vaccines remain pivotal during seasonal outbreaks, underscoring the necessity for annual immunization to minimize public health risks. Overall, these diverse applications underscore the dynamic nature of the market and highlight essential growth drivers such as increased awareness, ongoing Research and Development efforts, and the rising incidence of infectious diseases, all contributing to a robust framework for the US Human Vaccines Market revenue generation.
The Administration Route segment of the US Human Vaccines Market plays a critical role in the effective delivery of vaccines to the population, ensuring efficient immunization against various diseases. This segment encompasses multiple methods such as Intramuscular, Subcutaneous, Oral, and Intradermal routes, each with its own set of advantages and suitable applications. Intramuscular administration remains a dominant choice due to its efficacy in delivering vaccines, particularly for those requiring deeper tissue entry for optimal immune response.
Subcutaneous administration offers ease of use and patient comfort, making it favorable in certain vaccination scenarios. The Oral route is increasingly appreciated for its non-invasive nature, allowing for easier administration, especially in pediatric and mass immunization campaigns. Intradermal delivery is gaining traction, particularly for specific vaccines, due to its potential for reduced dosage while maintaining immunogenicity. Overall, the Administration Route segment is essential for driving market growth and ensuring that vaccination efforts are both accessible and effective, addressing the healthcare needs of the US population through a range of delivery methods tailored to various situations and demographics. Factors such as advancements in vaccine technology, public health initiatives, and increasing awareness of vaccination benefits further contribute to the expansion of this market segment.
The US Human Vaccines Market, focusing on Target Diseases, encompasses a variety of critical health threats that necessitate vaccination strategies. Infectious diseases remain a predominant concern, with illnesses such as influenza, COVID-19, and various childhood vaccinations significantly driving market demand. Vaccination for oncological diseases is gaining traction as advancements in immunotherapy are opening new avenues to prevent and treat cancers, leading to increased investments in Research and Development.
Autoimmune diseases present a unique challenge, with a growing understanding of their underlying mechanisms prompting increased focus on developing targeted vaccinations. Each of these areas presents substantial opportunities for growth, influenced by rising healthcare costs and a heightened emphasis on preventive care. Collaborative efforts among healthcare providers and governments are vital, with statistics showing vaccine efficacy can significantly reduce the burden of these diseases. Overall, the Target Diseases segment plays an essential role in shaping public health strategies and improving population health outcomes across the US.
The competitive landscape of the US Human Vaccines Market is characterized by a dynamic interplay of established pharmaceutical giants and innovative biotech firms. The market is driven by increasing public awareness of vaccine developments, government initiatives to improve vaccination rates, and the growing prevalence of infectious diseases. Amidst the backdrop of the COVID-19 pandemic, the importance of effective vaccines has gained unprecedented recognition, leading to heightened competition and significant investment in vaccine research and development. Companies are now focusing on expanding their product portfolios, leveraging advanced technologies, and forming strategic partnerships to enhance their market positions. As a result, the competitive insights reveal a landscape marked by innovation, rigorous regulatory scrutiny, and a commitment to public health, with companies striving to address the evolving needs of patients and healthcare systems.
Merck and Co holds a prominent position in the US Human Vaccines Market, supported by its comprehensive pipeline of vaccines that cater to various infectious diseases. With a rich history of vaccine development, the company's strengths lie in its strong brand reputation, extensive research capabilities, and established distribution networks. Merck is known for its flagship vaccines, which have consistently demonstrated efficacy and safety, earning the trust of both healthcare providers and the public.
The company continues to invest significantly in R&D activities to introduce next-generation vaccines, and its ability to rapidly respond to emerging health threats positions it as a leader in the field. Furthermore, Merck's strategic collaborations with academic institutions and government agencies enhance its capabilities to innovate and stay ahead of competitors in this ever-evolving market.
Vaxart is an emerging player in the US Human Vaccines Market, focused on developing oral vaccines that offer unique advantages over traditional injectable options. The company's proprietary technology platform allows for the design of vaccines that are stable at room temperature, addressing logistical challenges associated with cold-chain storage. Key products under development include oral vaccines for respiratory viruses, which have shown promise in preclinical studies.
Vaxart's strengths lie in its innovative approach to vaccine delivery, potentially improving vaccine acceptance and adherence among populations. The company's presence in the market is reinforced by strategic partnerships aimed at enhancing its research and development capabilities. Additionally, Vaxart's commitment to advancing its vaccine candidates through clinical trials reflects its ambition to contribute to the broader vaccination landscape in the US. The company’s recent collaborations and potential mergers indicate its strategy to leverage synergies that can further its market position as it navigates the complex regulatory environment of vaccine approval and distribution.
As of recent months, the US Human Vaccines Market has witnessed significant developments, particularly in response to ongoing global health challenges. In October 2023, Pfizer and Moderna reported increased production capabilities for their mRNA vaccines, focused on addressing proposed booster shots for emerging variants. Merck and Co has intensified its Research and Development efforts in vaccine therapeutics, focusing on collaborations with biotech firms to expedite vaccine innovation. AstraZeneca's vaccine collaboration with various health entities has led to expanding distribution networks in underserved populations across the United States.
In terms of mergers and acquisitions, in August 2023, Novavax completed its acquisition of a biotechnological firm specializing in vaccine delivery systems to enhance its product pipeline. There have also been reports of increased valuations for companies such as GlaxoSmithKline and Johnson and Johnson, fueled by enhanced funding for vaccine accessibility and newer product developments aimed at combating infectious diseases. The market growth has been positively impacted by regulatory support from US health agencies, stimulating demand for diverse vaccine options, as the country remains vigilant against potential influenza surges and new viral threats. Overall, these activities signify a dynamic phase in the US Human Vaccines Market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 9.72(USD Billion) |
| MARKET SIZE 2024 | 10.5(USD Billion) |
| MARKET SIZE 2035 | 17.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.478% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Merck and Co, Vaxart, AstraZeneca, Seqirus, GlaxoSmithKline, Inovio Pharmaceuticals, Horizon Therapeutics, Moderna, Vaccinex, Pfizer, AbbVie, Sanofi, Johnson and Johnson, Novavax, Bayer |
| SEGMENTS COVERED | Vaccine Type, Application, Administration Route, Target Diseases |
| KEY MARKET OPPORTUNITIES | Increased vaccine development funding, Expansion of personalized vaccines, Growth in adult vaccination rates, Emergence of mRNA technology, Rising demand for global vaccination access |
| KEY MARKET DYNAMICS | Regulatory approvals and compliance, Increasing vaccination awareness, Advancements in vaccine technology, Rising prevalence of infectious diseases, Government funding and support |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Human Vaccines Market is expected to be valued at 10.5 billion USD in 2024.
By 2035, the overall market is anticipated to reach a value of 17.0 billion USD.
The anticipated CAGR for the US Human Vaccines Market from 2025 to 2035 is 4.478%.
In 2024, the Inactivated vaccines segment is valued at 4.2 billion USD, making it the largest share in the market.
The Live Attenuated vaccines segment is expected to reach 4.0 billion USD in 2035.
Major players in the market include Merck and Co, Pfizer, and Moderna among others.
The Subunit vaccines market is expected to be valued at 2.4 billion USD in 2035.
The Recombinant vaccines segment is projected to grow to 2.9 billion USD in 2035.
Key growth drivers include rising awareness of vaccination and advancements in vaccine technology.
The Toxoid vaccines segment is valued at 0.5 billion USD in 2024.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
